FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
Pancreatic adenocarcinoma (PAC) incidence increases regularly in Western countries and it is
expected to become the second leading cause of cancer-related mortality in 2020. The
prognosis of this disease remains very poor with an overall 5-year survival rate less than
5%.
The FOLFIRINOX regimen (5-fluorouracil [5-FU], folinic acid, irinotecan, and oxaliplatin) and
the combination of nab-paclitaxel with gemcitabine demonstrated to be more effective than
gemcitabine alone, and are both validated as standard first-line treatment options for
metastatic PAC. However, the use of FOLFIRINOX is limited to patients with ECOG performance
status (PS) 0-1 and aged less than 75 years. Nab-paclitaxel is currently not reimbursed in
France.